Controlled Human Infection Model Challenge/Rechallenge
Controlled Human Infection Model Challenge/Rechallenge: Shigella Flexneri 2a and S. Sonnei Cross-protective Antigens Discovery in Healthy Adults in the United States
Sponsor: Johns Hopkins University Center for Immunization Research (CIR)
A PHASE1 clinical study on Shigellosis, this trial is completed. The trial is conducted by Johns Hopkins University Center for Immunization Research (CIR) and has accumulated 9 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Feb 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Feb 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Dec 2023 — Jul 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Apr 2023 — Dec 2023 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
▶ Show 4 earlier versions
-
May 2022 — Apr 2023 [monthly]
Recruiting PHASE1
-
Jan 2022 — May 2022 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Oct 2021 — Jan 2022 [monthly]
Not Yet Recruiting PHASE1
-
Sep 2021 — Oct 2021 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Johns Hopkins University Center for Immunization Research (CIR)
- PATH
- United States Department of Defense
For direct contact, visit the study record on ClinicalTrials.gov .